"For 2026, we are maintaining our cash operating expense guidance of less than $390 million." (CFO & President of Recursion UK Taylor). "We expect multiple clinical readouts over the next 12 to 18 ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

Good morning, everyone, and thank you for joining us. Since stepping into this role, I've been focused on a singular question: how do we harness the full power of AI to consistently and with urgency ...

Earnings call Recursion Pharmaceuticals delivered strong operational progress with a 30% YoY reduction in operating expenses and an extended cash runway into early 2028. Clinical momentum was ...

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he ...

A research team at Mohamed bin Zayed University of Artificial Intelligence published a finding in April 2026 that has gained traction in engineering circles for reasons that go beyond its headline ...

Google reported the first confirmed AI-assisted zero-day exploit, raising new concerns about logic flaws, supply chain risk, and containment.

Zaya1-8B is a huge shift in LLMs, and the results are impressive.

The backrooms consist of a series of spaces that feel “off,” a concept popularized online under the term “liminal space.” ...

Once you're in, you're in.